top of page

European Hub for Advanced Development in Regenerative Medicine and Biomaterials (EHAB)

The European Hub for Advanced Development in Regenerative Medicine and Biomaterials (EHAB) aims to accelerate the delivery of innovative health techniques and products in the area of advanced therapies/regenerative medicine and biomaterials to citizens and patients who need it.

EHAB Vision

EHAB’s Vision is to strengthen the European landscape in Advanced Therapies and Biomaterials (AT&B) by building a European interconnected value chain and powerhouse to making cell and tissue related therapies available to all European citizens, seizing opportunities in key parts of the AT&B value chain, consolidating EU assets, notably SMEs and increasing its international competitiveness.

EHAB Mission

EHAB’s mission is to identify regional strengths, weaknesses, gaps and needs in a consolidated transregional AT&B value chain and to elaborate a joint action plan to strengthen the performance and capacity of the innovation ecosystems of e.g. SME’s innovation stakeholders and their efficient interconnection and their alignment towards EU-level priorities, jointly tackling challenges at EU, national, regional, and local level together with all the quadruple helix stakeholders.ant to share. Be sure to include relevant skills you gained, accomplishments you achieved or milestones you reached during your education.

Participants EHAB

  • ReGEN Biomedical via the Brightlands Biomedical Ecosystem represented by Brightlands Maastricht Health Campus, The Netherlands

  • Brabant Development Agency (BOM), The Netherlands)

  • Flanders.BIO, Belgium

  • BioRegio STERN, Germany

  • A4tec-association (A4TEC), Portugal

  • BIOCAT, Spain

  • Resarch Institutes of Sweden AB (RISE), Sweden

  • MedSilesia, Gornslaski Akcelerator Przedsiebiorczosci Rynkowej sp z o.o. (GAPR), Poland

EHAB is endorsed by several regional and European level organisations, including : the Province of North-Brabant, the Province of Limburg, the RegMed XB consortium, the department of Economy, Science and Innovation of the Flemish Government, the Smart Health Pilot of the Vanguard Initiative, the Health Department from the Generalitat de Catalunya, Leitat, ASEBIO, the Vall d’Hebron Institute of Oncology, the Fraunhofer-Institut für Produktionstechnik und Automatisierung (Fraunhofer IPA), and the Marshall Office of the Silesia Voivodeship.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Commission as the granting authority. Neither the European Union nor the granting authority can be held responsible for them.

bottom of page